Market closedNon-fractional
Phathom Pharmaceuticals/PHAT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ticker
PHAT
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Florham Park, United States
Employees
452
Website
www.phathompharma.com
PHAT Metrics
BasicAdvanced
$660M
Market cap
-
P/E ratio
-$4.46
EPS
0.67
Beta
-
Dividend rate
Price and volume
Market cap
$660M
Beta
0.67
Financial strength
Current ratio
7.831
Quick ratio
7.504
Long term debt to equity
-310.797
Total debt to equity
-322.385
Interest coverage (TTM)
-4.15%
Management effectiveness
Return on assets (TTM)
-51.74%
Return on equity (TTM)
206.65%
Valuation
Price to revenue (TTM)
240.445
Price to book
-4.41
Price to tangible book (TTM)
-4.41
Price to free cash flow (TTM)
-3.704
Growth
Earnings per share change (TTM)
-7.99%
3-year earnings per share growth (CAGR)
1.98%
What the Analysts think about PHAT
Analyst Ratings
Majority rating from 9 analysts.
PHAT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.9M
216.67%
Net income
-$83M
4.15%
Profit margin
-4,357.89%
-67.11%
PHAT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.84
-$0.76
-$1.39
-$1.42
-
Expected
-$0.98
-$0.89
-$1.08
-$1.31
-$1.38
Surprise
-14.16%
-14.74%
29.06%
8.47%
-
PHAT News
AllArticlesVideos
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
GlobeNewsWire·1 week ago
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Seeking Alpha·1 month ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phathom Pharmaceuticals stock?
Phathom Pharmaceuticals (PHAT) has a market cap of $660M as of July 27, 2024.
What is the P/E ratio for Phathom Pharmaceuticals stock?
The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of July 27, 2024.
Does Phathom Pharmaceuticals stock pay dividends?
No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Phathom Pharmaceuticals dividend payment date?
Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.
What is the beta indicator for Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Phathom Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.